Poseida Therapeutics Inc (PSTX)

Currency in USD
9.500
0.000(0.00%)
Closed·
Showing Poseida historical data. For real-time data please try another search
Day's Range
9.4939.670
52 wk Range
1.8709.670
Key Statistics
Prev. Close
9.5
Open
9.58
Day's Range
9.493-9.67
52 wk Range
1.87-9.67
Volume
-
Average Volume (3m)
1.85M
1-Year Change
208.44%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Poseida Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Poseida Therapeutics Inc Company Profile

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California. As of January 7, 2025, Poseida Therapeutics, Inc. operates as a subsidiary of Roche Holdings, Inc.

Poseida Therapeutics Inc SWOT Analysis


Innovative Pipeline
Poseida's diverse gene therapy and CAR-T programs show promise, with positive early-stage data in multiple myeloma and hereditary angioedema treatments
Financial Strength
Robust cash position of $264 million expected to fund operations into 2025, bolstered by strategic partnerships with Astellas and Roche
Analyst Optimism
Explore bullish sentiment with price targets ranging from $10 to $20, reflecting confidence in Poseida's technology and market potential
Strategic Partnerships
Learn how collaborations with industry giants like Roche are advancing Poseida's allogeneic CAR-T therapies and enhancing market positioning
Read full SWOT analysis

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-- / -0.46
Revenue / Forecast
-- / 15.00M
EPS Revisions
Last 90 days

PSTX Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.